search
Back to results

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Primary Purpose

Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Nivolumab
Ipilimumab
Sponsored by
Dana-Farber Cancer Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hodgkin Lymphoma focused on measuring Hodgkin lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must have histologically determined classic Hodgkin lymphoma with pathologic review at the participating institution.
  • Participants must have measurable disease, defined as a lymph node or tumor mass ≥1.5 cm in at least one dimension by CT, PET/CT, or MR. Imaging must have been completed no greater than 6 weeks prior to study enrollment. Measurable disease that has previously been irradiated is permissible only if there has been evidence of progression since the radiation.
  • Patients must have progressed after two or more lines of systemic treatment, including autologous stem cell transplantation, if eligible.
  • Patients must have received a prior PD-1 monoclonal antibody, with the following specific requirements for each cohort.

    • Cohort 1

      • Received at least 18 weeks of single-agent PD-1 mAb (with last dose within 12 weeks)
      • Underwent a restaging PET scan at least 18 weeks after initiation of PD-1 monotherapy which demonstrated:

        • Partial response or stable disease (based on Lugano criteria)
        • Note: Patients achieving an indeterminate response based on LYRIC criteria(23) on an initial staging PET scan are eligible if they achieve stable disease (<10% increase in tumor burden and <50% decrease in tumor burden) or a partial response on a subsequent staging PET scan.
    • Cohort 2

      • Progression of disease or relapse following treatment with nivolumab or pembrolizumab. Intervening treatments between PD-1 mAb therapy and the trial are permitted.
  • Patients may have had a prior autologous stem cell transplant and may have been treated with chimeric antigen receptor T-cells (CAR T-cells).
  • Age ≥18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (see Appendix A)
  • Adequate hematologic and organ function as defined below:

    • Absolute neutrophil count > 1.0x109/L unless due to marrow involvement by lymphoma in which case ANC must be >0.75x109/L. Growth factor support is allowed provided it is received at least 5 days prior to enrollment labs.
    • Platelets > 75 x109/L, unless due to marrow involvement by lymphoma, in which case platelets must be >50 x109/L
    • Estimated GFR (by Cockroft-Gault equation) > 40ml/min
    • Total bilirubin < 1.5 X ULN
    • AST/ALT < 2.5 X ULN
  • Ability to understand and the willingness to sign a written informed consent document.
  • Willingness to provide pre-treatment tumor sample by core needle or excisional surgical biopsy. An archival sample is acceptable in the following situations: the sample was acquired within 90 days of initiation of PD-1 therapy AND the following provisions are met: 1) availability of a tumor-containing formalin fixed, paraffin embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut and mounted on positively charged glass slides (SuperFrost Plus are recommended). Preferably, 25 slides should be provided; if not possible, a minimum of 15 slides is required. Exceptions to this criterion may be made with approval of the Study Chair.
  • Willingness to use contraception during and after study treatment. Women of child-baring potential (WOCBP) will be instructed to adhere to contraception for a period of 5 months following last dose of nivolumab and 6 months following the last dose of ipilimumab. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after last dose of nivolumab and 6 months after the last dose of ipilimumab.

Exclusion Criteria:

  • Patients currently receiving anticancer therapies or who have received anticancer therapies within 28 days of the start of study drug (including chemotherapy, radiation therapy, antibody-based therapy, etc.), or 56 days for radioimmunotherapy (Note: Patients in Cohort 1 may have received a PD-1 mAb within 3 weeks of study initiation). Steroids for symptom palliation are allowed but must be either discontinued or on stable doses of < 10mg daily of prednisone (or the equivalent) at the time of initiation of protocol therapy.
  • Patients may not be receiving any other investigational agents or have received investigational agents within 4 weeks (or 3 half-lives, whichever is longer) of beginning treatment.
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitization.
  • Patients who have undergone prior allogeneic stem cell transplantation
  • Patients with a history of or active autoimmune disease (except controlled asthma, Hashimoto thyroiditis, atopic dermatitis, or vitiligo), or requiring systemic corticosteroids at a dose of 10mg prednisone equivalent daily. Patients with a history of autoimmune disease who never required corticosteroids and with no evidence of disease activity, and in whom the risk of reactivation is felt not to be serious, may be enrolled after discussion with the overall study chair. Exceptions to this are patients with a history of inflammatory bowel disease (ulcerative colitis and Crohn's disease). These patients are excluded regardless of whether their disease is active or inactive.
  • Patients who experienced grade 4 immune-related adverse events (irAEs) during treatment with a PD-1 mAb.
  • Patients with active pneumonitis or colitis, or patients with cirrhosis.
  • Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).
  • Patients with known HIV infection or hepatitis B or C infection. Testing for HIV is optional. Testing for hepatitis B and C is mandatory. Patients with hepatitis B core Ab positivity but negative surface antigen and negative viral load may be enrolled if they can be treated with a prophylactic agent (eg, entecavir); patients with hepatitis C seropositivity who have a negative viral load can also be enrolled.
  • Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
  • Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 2 years. Patients with prostate cancer are allowed if PSA is less than 1.
  • Patients should not have received immunization with attenuated live vaccine within one week of study entry or during study period.
  • History of noncompliance to medical regimens.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study.
  • Patients with any one of the following currently on or in the previous 6 months will be excluded: myocardial infarction, congenital long QT syndrome, torsade de pointes, left anterior hemiblock, unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident.
  • Other uncontrolled intercurrent illness that would limit adherence to study requirements.

Sites / Locations

  • University of Chicago MedicineRecruiting
  • Massachusetts General HospitalRecruiting
  • Brigham and Women's HospitalRecruiting
  • Dana-Farber Cancer InstituteRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Disease Progression after previous therapy

Arm Description

Participants will receive Ipilimumab alone and depending on response will receive either a maintenance course of Ipilimumab or a course of Nivolumab and Ipilimumab in combination followed by a maintenance course of Ipilimumab. Patients who have progressive disease after fewer than 4 cycles of ipilimumab are also eligible to proceed to combination therapy with nivolumab and ipilimumab, if they are clinically stable. Ipilimumab Monotherapy: Every 3 weeks for 4 study cycles Complete Response/Partial Response: Maintenance Ipilimumab every 12 weeks for 8 cycles Stable or Progressive Disease Response: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles, followed by Maintenance Ipilimumab every 12 weeks for 7 cycles

Outcomes

Primary Outcome Measures

Overall response rate (ORR) after 4 cycles of ipilimumab monotherapy
Assessed by PET/CT (using Lugano criteria and LYRIC criteria)

Secondary Outcome Measures

Overall response rate (ORR) Ipilimumab monotherapy
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab monotherapy
Partial Response rate (PRR) Ipilimumab monotherapy
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after 4 ipilimumab monotherapy
Complete Response rate (CRR) Ipilimumab monotherapy
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab monotherapy
Overall response rate (ORR) ipilimumab and nivolumab combination therapy
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab and nivolumab combination therapy
Partial Response rate (PRR) ipilimumab and nivolumab combination therapy
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab and nivolumab combination therapy
Complete Response rate (CRR) ipilimumab and nivolumab combination therapy
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab and nivolumab combination therapy
Duration of Response ipilimumab maintenance
Using Lugano criteria and LYRIC criteria
Duration of Response ipilimumab and nivolumab combination therapy
Using Lugano criteria and LYRIC criteria
Progression-free survival
Lugano criteria and LYRIC criteria
Overall Survival
Lugano criteria and LYRIC criteria
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0
Descriptions and grading scales per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Full Information

First Posted
June 8, 2021
Last Updated
October 18, 2023
Sponsor
Dana-Farber Cancer Institute
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT04938232
Brief Title
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Official Title
A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 4, 2021 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
August 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dana-Farber Cancer Institute
Collaborators
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: Ipilimumab Nivolumab
Detailed Description
This is an open-label, multi-center, phase II study of ipilimumab with or without nivolumab for patients with relapsed or refractory (R/R) classic Hodgkin lymphoma (cHL). Nivolumab is a drug which is approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients experiencing relapsed Hodgkin lymphoma (cHL) who have received at least two prior systemic therapies. Ipilimumab has been approved by the FDA for the treatment of metastatic melanoma (a type of skin cancer), and specific types of previously treated advanced kidney cancers. The study drugs have not been approved in combination for cHL by the Food and Drug Administration (FDA). This study is for participants who previously had progressive disease when receiving a PD-1 mAb. Participants will receive 4 cycles of ipilimumab monotherapy and then undergo restaging imaging. Patients who achieved an objective response will continue treatment with ipilimumab maintenance. Other patients will receive 4 cycles of nivolumab and ipilimumab followed by ipilimumab maintenance treatment. Patients who have progressive disease after fewer than 4 cycles of ipilimumab are eligible to proceed to combination therapy with nivolumab and ipilimumab if they are clinically stable. Participants will receive up to ~ 24 months of study treatment. After completion of therapy, participants will be followed every 3 months for 2 years and then every 6 months for the next 5 years. It is expected that about 13 people will participate in this research study. Bristol Myers Squibb (BMS) is supporting this research study by providing the study drugs and funding for the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
Keywords
Hodgkin lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
13 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Disease Progression after previous therapy
Arm Type
Experimental
Arm Description
Participants will receive Ipilimumab alone and depending on response will receive either a maintenance course of Ipilimumab or a course of Nivolumab and Ipilimumab in combination followed by a maintenance course of Ipilimumab. Patients who have progressive disease after fewer than 4 cycles of ipilimumab are also eligible to proceed to combination therapy with nivolumab and ipilimumab, if they are clinically stable. Ipilimumab Monotherapy: Every 3 weeks for 4 study cycles Complete Response/Partial Response: Maintenance Ipilimumab every 12 weeks for 8 cycles Stable or Progressive Disease Response: Nivolumab and Ipilimumab every 3 weeks for 4 study cycles, followed by Maintenance Ipilimumab every 12 weeks for 7 cycles
Intervention Type
Drug
Intervention Name(s)
Nivolumab
Other Intervention Name(s)
Opdivo
Intervention Description
Intravenous infusion
Intervention Type
Drug
Intervention Name(s)
Ipilimumab
Other Intervention Name(s)
Yervoy
Intervention Description
Intravenous infusion
Primary Outcome Measure Information:
Title
Overall response rate (ORR) after 4 cycles of ipilimumab monotherapy
Description
Assessed by PET/CT (using Lugano criteria and LYRIC criteria)
Time Frame
From enrollment to completion of 4 cycles (each cycle is 21 days) of treatment
Secondary Outcome Measure Information:
Title
Overall response rate (ORR) Ipilimumab monotherapy
Description
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab monotherapy
Time Frame
12 weeks
Title
Partial Response rate (PRR) Ipilimumab monotherapy
Description
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after 4 ipilimumab monotherapy
Time Frame
12 weeks
Title
Complete Response rate (CRR) Ipilimumab monotherapy
Description
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab monotherapy
Time Frame
12 weeks
Title
Overall response rate (ORR) ipilimumab and nivolumab combination therapy
Description
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab and nivolumab combination therapy
Time Frame
24 weeks
Title
Partial Response rate (PRR) ipilimumab and nivolumab combination therapy
Description
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab and nivolumab combination therapy
Time Frame
24 weeks
Title
Complete Response rate (CRR) ipilimumab and nivolumab combination therapy
Description
Assessed by PET/CT (using Lugano criteria and LYRIC criteria) after ipilimumab and nivolumab combination therapy
Time Frame
24 weeks
Title
Duration of Response ipilimumab maintenance
Description
Using Lugano criteria and LYRIC criteria
Time Frame
2 years
Title
Duration of Response ipilimumab and nivolumab combination therapy
Description
Using Lugano criteria and LYRIC criteria
Time Frame
2 years
Title
Progression-free survival
Description
Lugano criteria and LYRIC criteria
Time Frame
2 years
Title
Overall Survival
Description
Lugano criteria and LYRIC criteria
Time Frame
2 years
Title
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0
Description
Descriptions and grading scales per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must have histologically determined classic Hodgkin lymphoma with pathologic review at the participating institution. Participants must have measurable disease, defined as a lymph node or tumor mass ≥1.5 cm in at least one dimension by CT, PET/CT, or MR. Imaging must have been completed no greater than 6 weeks prior to study enrollment. Measurable disease that has previously been irradiated is permissible only if there has been evidence of progression since the radiation. Patients must have progressed after two or more lines of systemic treatment, including autologous stem cell transplantation, if eligible. Progression of disease or relapse following treatment with nivolumab or pembrolizumab. Intervening treatments with between PD-1 mAb therapy and the trial are permitted. Patients may have had a prior autologous stem cell transplant and may have been treated with chimeric antigen receptor T-cells (CAR T-cells). Age ≥18 years. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (see Appendix A) Adequate hematologic and organ function as defined below: Absolute neutrophil count > 1.0x109/L unless due to marrow involvement by lymphoma in which case ANC must be >0.75x109/L. Growth factor support is allowed provided it is received at least 5 days prior to enrollment labs. Platelets > 75 x109/L, unless due to marrow involvement by lymphoma, in which case platelets must be >50 x109/L Estimated GFR (by Cockroft-Gault equation) > 40ml/min Total bilirubin < 1.5 X ULN AST/ALT < 2.5 X ULN Ability to understand and the willingness to sign a written informed consent document. Willingness to provide pre-treatment tumor sample by core needle or excisional surgical biopsy. An archival sample is acceptable in the following situations: the sample was acquired within 90 days of initiation of PD-1 therapy AND the following provisions are met: 1) availability of a tumor-containing formalin fixed, paraffin embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut and mounted on positively charged glass slides (SuperFrost Plus are recommended). Preferably, 25 slides should be provided; if not possible, a minimum of 15 slides is required. Exceptions to this criterion may be made with approval of the Study Chair. Willingness to use contraception during and after study treatment. Women of child-baring potential (WOCBP) will be instructed to adhere to contraception for a period of 5 months following last dose of nivolumab and 6 months following the last dose of ipilimumab. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after last dose of nivolumab and 6 months after the last dose of ipilimumab. Exclusion Criteria: Patients currently receiving anticancer therapies or who have received anticancer therapies within 28 days of the start of study drug (including chemotherapy, radiation therapy, antibody-based therapy, etc.), or 56 days for radioimmunotherapy. Steroids for symptom palliation are allowed but must be either discontinued or on stable doses of < 10mg daily of prednisone (or the equivalent) at the time of initiation of protocol therapy. Patients may not be receiving any other investigational agents or have received investigational agents within 4 weeks (or 3 half-lives, whichever is longer) of beginning treatment. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitization. Patients who have undergone prior allogeneic stem cell transplantation Patients with a history of or active autoimmune disease (except controlled asthma, Hashimoto thyroiditis, atopic dermatitis, or vitiligo), or requiring systemic corticosteroids at a dose of 10mg prednisone equivalent daily. Patients with a history of autoimmune disease who never required corticosteroids and with no evidence of disease activity, and in whom the risk of reactivation is felt not to be serious, may be enrolled after discussion with the overall study chair. Exceptions to this are patients with a history of inflammatory bowel disease (ulcerative colitis and Crohn's disease). These patients are excluded regardless of whether their disease is active or inactive. Patients who experienced grade 4 immune-related adverse events (irAEs) during treatment with a PD-1 mAb. Patients with active pneumonitis or colitis, or patients with cirrhosis. Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia). Patients with known HIV infection or hepatitis B or C infection. Testing for HIV is optional. Testing for hepatitis B and C is mandatory. Patients with hepatitis B core Ab positivity but negative surface antigen and negative viral load may be enrolled if they can be treated with a prophylactic agent (eg, entecavir); patients with hepatitis C seropositivity who have a negative viral load can also be enrolled. Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 2 years. Patients with prostate cancer are allowed if PSA is less than 1. Patients should not have received immunization with attenuated live vaccine within one week of study entry or during study period. History of noncompliance to medical regimens. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study. Patients with any one of the following currently on or in the previous 6 months will be excluded: myocardial infarction, congenital long QT syndrome, torsade de pointes, left anterior hemiblock, unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident. Other uncontrolled intercurrent illness that would limit adherence to study requirements.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Reid W Merryman, MD
Phone
617-632-6844
Email
Reid_Merryman@dfci.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Celeste A Carey, MS
Phone
857-215-1646
Email
celeste_carey@dfci.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Reid W Merryman, MD
Organizational Affiliation
Dana-Farber Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Chicago Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Justin Kline, MD
Phone
773-702-4400
Email
jkline@bsd.uchicago.edu
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeremy S Abramson, MD
Phone
617-726-8743
Email
jabramson@partners.org
First Name & Middle Initial & Last Name & Degree
Jeremy Abramson, MD
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Reid W Merryman, MD
Phone
617-632-6844
Email
Reid_Merryman@dfci.harvard.edu
First Name & Middle Initial & Last Name & Degree
Reid W Merryman, MD
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Reid W Merryman, MD
Phone
617-632-6844
Email
Reid_Merryman@dfci.harvard.edu
First Name & Middle Initial & Last Name & Degree
Reid W Merryman, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD Sharing Time Frame
Data can be shared no earlier than 1 year following the date of publication
IPD Sharing Access Criteria
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Learn more about this trial

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

We'll reach out to this number within 24 hrs